Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-GD2 monoclonal antibody BCD-245

A monoclonal antibody directed against the tumor-associated antigen (TAA) disialoganglioside (GD2; GD-2), with potential antineoplastic activity. Upon administration, anti-GD2 monoclonal antibody BCD-245 may induce cytotoxicity in GD2-expressing tumor cells by antibody-dependent cell-mediated cytotoxicity (ADCC). GD2 is overexpressed on the surface of neuroblastoma (NB) cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-GD-2 monoclonal antibody BCD-245
Code name:BCD 245
BCD-245
BCD245
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search